Fujifilm to accelerate the manufacturing of Avigan to treat COVID-19
By Akshay Kedari  Date: 2020-04-16

Fujifilm to accelerate the manufacturing of Avigan to treat COVID-19

Fujifilm, a renowned Japanese pharmaceutical company, has reportedly announced plans to boost the production of Avigan, an antiviral drug said to be a possible therapy for coronavirus. Avigan is primarily used to treat Influenza.

The company is aiming to provide this drug in large quantities in order to meet the nationwide growing need for antiviral drugs. The company hopes to produce hundreds of thousands of Avigan doses during the coming months.

The drug maker is currently increasing its production capacity in its Toyoma facility to accelerate the production rate. Since the company is planning large-scale production for Avigan, it has created strategic collaborations with international and domestic firms to provide the raw material for manufacturing Avigan and has also added capacity at its Mako Pure Chemical Co. unit to manufacture active pharmaceutical ingredients of the drug.

Since Fujifilm will now have its massive production in place, it is expecting to produce 100,000 Avigan treatments courses ready for use by July. This number of 3.5 times Avigan’s supply in March and the company has further plans to manufacture 300,000 regimens in place by September.

Japanese drug maker, last month, stated its intentions to accelerate the production of Avigan, after the news made a global impact. However, the company also made some clarifications about its use. The company particularly specified that the Influenza treatment drug has never been distributed in any market and that it is not available in any pharmacies and hospitals across Japan as well as overseas.

Avigan is an antiviral drug developed by the Toyama Chemical unit of Fujifilm and it received approval for sale back in 2014 to treat influenza. However, it was told that this drug can only be used when all other treatments turn out to be ineffective against a re-emerging or novel influenza virus.

While talking about this drug, Shinzo Abe, the Prime Minister of Japan stated that the government would soon initiate tests of Avigan in coronavirus patients in collaboration with other nations and simultaneously accelerate the production while aiming a faster approval for the drug.

Source credit: https://www.fiercepharma.com/manufacturing/fujifilm-speeds-production-potential-covid-19-therapy-avigan

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Rivian secures USD 2.65 billion months before its first vehicle launch
Rivian secures USD 2.65 billion months before its first vehicle launch
By Akshay Kedari

Electric vehicle startup, Rivian, backed by Ford Motor Co. and Amazon.com Inc., has reportedly announced an investment round of USD 2.65 billion led by T. Rowe Price, months before its first vehicle launch. Sources with knowledge of the matter state...

BMW drivers can now unlock and start cars without using their iPhone
BMW drivers can now unlock and start cars without using their iPhone
By Akshay Kedari

German multinational automobile manufacturer, Bayerische Motoren Werke AG, commonly known as BMW, has reportedly unveiled an upgraded version of its mobile car key technology, called the Digital Key Plus. This product enables iPhone users to unlock t...

FMCG firms resort to marginal hike to cope with raw material inflation
FMCG firms resort to marginal hike to cope with raw material inflation
By Akshay Kedari

The recent inflation in raw materials has reportedly prompted players in the FMCG sector to take price hike measures for their products, in a bid to maintain the revenues. According to reliable sources, some FMCG companies, including Marico, have al...

boAt raises USD 100 million in funding from Warburg Pincus
boAt raises USD 100 million in funding from Warburg Pincus
By Akshay Kedari

Indian consumer electronics brand, boAt, has reportedly secured funding of USD 100 million from Warburg Pincus, a New-York-based private equity firm, at a USD 300 million valuation. The company will utilize these funds to expand its product portfoli...

Elevar Therapeutics and Inceptua partner to commercialize Apealea®
Elevar Therapeutics and Inceptua partner to commercialize Apealea®
By Akshay Kedari

According to reliable sources, U.S.-based fully integrated biopharmaceutical company, Elevar Therapeutics Inc., has signed an exclusive agreement with Inceptua Group for the commercialization and distribution of its non-cremophor based paclitaxel tre...